Earnings Report Digest

$ET has released its Q4 earnings, reporting EPS of $0.29, missing by $0.08, and revenue of $19.54B, down 4.83% YoY, missing by $1.87B. Key stats highlight adjusted EBITDA at $3.9B, showing growth, but concerns arise around declining crude oil segment revenue.

$ECL has released its Q4 2024 earnings, showcasing solid performance with an EPS of $1.81, just beating expectations, and revenues of $4.01B, a 1.70% increase YoY. The company achieved a 150 basis point rise in operating income margin, indicating improved profitability.

🚨 $DASH just released its Q4 2024 earnings! EPS of $0.89 missed expectations by $0.06, while revenue reached $2.87B—up 24.75% YoY, beating estimates by $25.45M. 👀

$MAR has released its Q4 2024 earnings, showing strong financial performance with an EPS of $2.45, beating estimates by $0.07, and revenue of $6.43B (up 5.48% Y/Y) beating expectations by $25.92M. 🌍

$SHOP has released its Q4 earnings report, showcasing strong revenue growth alongside some challenges. Revenue surged by 31% YoY to $2.81B, beating expectations, while EPS reflected a miss by $0.43. 📈 Notably, GMV grew 26% and free cash flow margins expanded to 22%, indicating solid financial health.

$SPGI has released its Q4 2024 earnings report, which shows stronger-than-expected results with an EPS of $3.77, exceeding estimates by $0.30, and revenue of $3.59B, representing a 14% increase YoY. Key highlights include notable growth rates across various segments, with Ratings revenue up 27% and a robust demand in Market Intelligence. However, there's cautious optimism due to geopolitical uncertainties and competitive pressures. 📈🚀

$KO reports strong Q4 earnings with EPS of $0.55, beating estimates by $0.03. Revenue reached $11.40B, up 4.17% year-over-year, exceeding expectations by $701.46M. Key stats show a solid valuation with a net debt leverage of 1.8x EBITDA, but currency headwinds remain a risk.

Trending stocks, Feb 11 2025

$VRTX has released its Q4 2024 earnings report, highlighting a revenue of $2.91B (+15.66% YoY) but an EPS of $3.98, missing estimates by $0.04. Key risks include rising expenses and potential IP issues outside the U.S. As for growth, Vertex is driving expansion with the launch of JOURNA VX and ALYFTREK, paving pathways for increased patient access. Future opportunities focus on penetrating the pain market and global CF therapies, yet competition remains. 📊💡 For more details, check valueverge.com/VRTX.

$MCD has released Q4 2024 earnings, showing an EPS of $2.83, just missing estimates by $0.03, with revenue at $6.39B, down 0.28% year-over-year. Key highlights include valuation challenges and a tough competition landscape, particularly impacted by a food safety incident.